As part of its mission, the Skin & Cancer Foundation Australia is committed to support and enhance research at the Foundation. The team, headed by Associate Professor Pablo Fernández-Peñas, are continuing to develop research activities at the Foundation by supporting a wider scope of research, including clinical trials, in-house projects, case studies and collaborative research projects. Furthermore, since the Foundation has a range of dermatologists with diverse specialties, the research topics studied are very different.

However, research at the Foundation would not be achievable without the generous support of our Partners. Since the Skin & Cancer Foundation Australia is a non-for-profit organisation, we rely on the support of others to help grow our research activities. The Foundations product partners program is one way that individuals and external companies can give back to the Foundation. When you support us directly or through our Partners, you support our common goal to make a difference in the lives of dermatology patients through clinical research.

Provided below is a list detailing some of the many publications from our staff at the Skin and Cancer Foundation Australia.

Publications:

  • First interim analysis of a randomised trial of whole brain radiotherapy in melanoma brain metastases confirms high data quality. Fogarty GB, Hong A, Dolven-Jacobsen K, Reisse C, Burmeister B, Haydu L, Dhillon H, Steel V, Shivalingam B, Drummond K, Vardy J, Nowak A, Hruby G, Scolyer R, Mandel C, Thompson JF. BMC Research Notes 2015, May 8, 8:192
  • Should patients with melanoma brain metastases receive adjuvant whole-brain radiotherapy? Gerald B Fogarty, Angela Hong, John F Thompson. The Lancet Oncology, Volume 16, Issue 5, May 2015, Pages e195-e196
  • The role of the follicular isthmus in the evolution of keratoacanthoma. Kossard S. J Cutan Pathol 2015, Apr;42(4):299-300.
  • Periorbital nodular fasciitis in Pregnancy – case report and literature review. Skippen B and Tumuluri K. Ophthalmic Plastic and Reconstructive Surgery; 2015 Feb 13.
  • Necrotizing dacryometaplasia: a rare lacrimal lesion mimicking malignancy. Skippen B, Gal A and Tumuluri K. Clin Experiment Ophthalmol. 2014 Dec 29. doi: 10.1111/ceo.12491.
  • Apple of the dermatologist’s eye. Sebaratnam DF. JAMA Dermatology Dec 2014:150(12):1280.
  • A diagnosis that will go down in history. Sebaratnam DF, Stewart NC, Venugopal SS. Medical Journal of Australia 2014:201(11); 697.
  • Cutaneous adverse effects of hormonal adjuvant therapy for breast cancer. Bock VL, Friedlander M Waring D, Kossard S, Wood GK. Australas J Dermatol 2014 Nov;55: 282-5.
  • Diffuse melanosis cutis in the setting of BRAF (V600E)metastatic melanoma. Sebaratnam DF, Martin LK, Venugopal SS, Cheung K et al. Int J Dermatol 2014 Nov; 53:1409-11.
  • Response regarding CLIPPERS. Kossard S, Smith A, Mathews Y et al. J Cutan Pathol. 2014 Sept; 41: 761.
  • Neurotropic T-cell lymphocytosis: a cutaneous expression of CLIPPERS. Smith A, Matthews Y, Kossard S, Turner J, Buckland ME, Parratt J. J Cutan Pathol 2014 Aug; 41: 657-62.
  • Accrual to a randomised trial of adjuvant whole brain radiotherapy for treatment of melanoma brain metastases is feasible. GB Fogarty, A Hong, K Dolven Jacobsen, CH Reisse, B Shivalingam, B Burmeister, LE Haydu, E Paton, JF Thompson. BMC Research Notes 2014 Jun 30, 7:412.
  • Surveillance for treatment failure of lentigo maligna with dermoscopy and in vivo confocal microscopy: new descriptors. Guitera, P., L. E. Haydu, S. W. Menzies, R. A. Scolyer, A. Hong, G. B. Fogarty, F. Gallardo, and S. Segura. Br J Dermatol. 2014 Jun;170(6):1305-12.
  • Mohs micrographic surgery for dermatofibrosarcoma protuberans (DFSP): A single-centre series of 76 patients treated by frozen-section Mohs micrographic surgery with a review of the literature Loghdey MS, Varma S, Rajpara SM, Al-Rawi H, Perks G, Perkins W. J Plast Reconstr Aesthet Surg. 2014 Oct;67(10):1315-21. doi:10.1016/j.bjps.2014.05.021. Epub 2014 May 23.
  • Low incidence of melanoma brain metastasis in the hippocampus. AM Hong, C Suoe, M Valenzuela, LE. Haydu, KD. Jacobsen, CH Reiss, G Fogarty. Rad Onc. 2014 Apr;111(1):59-62.
  • Radiotherapy for lentigo maligna: a literature review and recommendations for treatment. Fogarty, G. B., A. Hong, R. A. Scolyer, E. Lin, L. Haydu, P. Guitera, and J. Thompson. British Journal of Dermatology, 2014 Jan: 170(1) 52-58.
  • Symptomatic Histologically Proven Necrosis of Brain following Stereotactic Radiation and Ipilimumab in Six Lesions in Four Melanoma Patients. Stephanie Du Four, Angela Hong, Matthew Chan, et al., Case Reports in Oncological Medicine. 2014;2014:417913.
  • Primary Orbital Liposarcoma. Madge SN, Tumuluri K, Strianese D, Bonavolonta P, Wilcsek G, Dodd TJ, Selva D. Ophthalmology 117(3):606-14, 2010 Mar.
  • Mucinous sweat gland adenocarcinoma of the eyelid – Current knowledge of a rare tumour. Segal A, Segal N, Gal A and Tumuluri K. Orbit 29(6): 334-340, 2010.

Book Chapters 

  • Brain Metastases in Melanoma Patients: Treatment with Adjuvant Postoperative Whole-Brain Radiotherapy. G B. Fogarty A. Hong Ch 11. In: Part IV Brain Metastases in Melanoma; In: Brain Metastases from Primary Tumors, Ed: MA Hayat, Volume 2, Pgs 123-30, ISBN: 978-0-12-801419-6; posted 2014-12-30. Elsevier publishers.

DVD and Podcast

  • Interview podcast: Head and Neck Melanoma and Radiotherapy – Prof. G. Fogarty

    • iTunes link

    • Weblink

Presentations

  • Whole Brain Radiotherapy following local treatment of intracranial metastases of melanoma – a randomised phase III trial. G B Fogarty, 08.05 (WBRT): TROG 27th Annual Scientific Meeting, Newcastle, Australia, 24th – 26th March 2015 (Oral presentation)
  • HIV & Hepatitis: Effective control and risk minimisation in a dermatological setting. P. Faga. Australian Dermatology Association NSW State Conference October 2014.
  • A randomized controlled trial in T1N0 Merkel Cell Carcinoma of either radiotherapy to the primary site or wide local excision following diagnostic biopsy. G. Fogarty. NRP 05.14 ANZMTG ASM 9th Oct 2014 Perth.
  • Stereotactic Radiosurgery versus Observation for patients with Melanoma brain metastases being started on a BRAF Inhibitor (ROMA study). Gerald Fogarty. NRP 07.14 ANZMTG ASM 9th Oct 2014 Perth.
  • A randomised controlled multicentre trial of imiquimod versus radiotherapy for lentigo maligna when staged surgical excision with 5mm margins is not possible, is refused or fails. G. Fogarty ANZMTG 02.12 (RADICAL) 10-11 Oct SKMRC Mtg Perth.
  • Retrospective: Defining skin diseases. Kossard S. Division of Dermatolog Technicon University and Hospital September 2014 Haifa, Israel.
  • The Importance of Successful Collaborations. Kari Dolven-Jacobsen, Gerald B. Fogarty, Claudius H. Reisse, Elizabeth Paton, Victoria Steel, John F. Thompson Australia and New Zealand Melanoma Trials Group (ANZMTG). Presented at Nordic Melanoma Group 2014 4th/5th September in Turku, Finland.
  • Lecture Introduction to Radiation Oncology. G. Fogarty. Oncology Nurses SVH 15/8/14
  • Acquired perforating collagenosis. R. Minocha, D. Sebaratnam, A. Kurien. Australasian Society of Dermatopathology 35th Annual Meeting. Perth, Australia. August 24, 2014.
  • Epidermodysplasia verruciformis with typical clinicopathological findings. R. Minocha, D. Sebaratnam, J. Choi. Australasian Society of Dermatopathology 35th Annual Meeting. Perth, Australia. August 24, 2014.
  • The learning curve for stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT) service - experience from Genesis Cancer Care at Mater, Sydney. K Clarke, TChen, MA Izard, A Hong, GB Fogarty. Australian Brainlab RT User Group, 30 May - 1 June, 2014 Melbourne, Australia.
  • A cost-comparison of Mohs surgery and traditional excision for basal cell carcinoma in Australia. D. Sebaratnam, B. Choy, M Lee et al. Australasian College of Dermatologists’ Annual Scientific Meeting. Melbourne, Australia. May 17, 2014.
  • A cost-utility analysis of Mohs surgery versus traditional excision for head and neck basal cell carcinoma: an update. B. Choy, R. Morton, D. Sebaratnam, et al. Australasian College of Dermatologists’ Annual Scientific Meeting. Melbourne, Australia. May 17, 2014.
  • Patient Education Strategies in a dermatology surgery setting – what are the challenges? P. Faga. Australian Dermatology Association National Conference May 2014.
  • Resuscitation Equipment & Emergency Drugs: Crashing Patient: Where's the black box? P. Faga. Australian Dermatology Association National Conference May 2014.
  • Retrospective: Defining skin diseases. Kossard S. North American Clinical Dermatology Society February 2014 Panama City.
  • Fractional Laser. Michelle Hunt. The Facts of Light Advanced Symposium 2014.
  • Rosacea: Diagnosis and Management. M. Hunt. Inner West GP Symposium 2014.
  • Whole Brain Radiotherapy following local treatment of intracranial metastases of melanoma - A randomised phase III trial (WBRTMel) - Progress Update. G. Fogarty. ANZMTG 01.07 10-11 Oct SKMRC Mtg Perth, 2014.
  • Orbital Xanthogranuloma and Erdheim Chester Disease – case report and literature review. Moorthy S, Taylor S and Tumuluri K. Accepted as poster for ESOPRS 2014 meeting, Budapest.
  • Periorbital nodular fasciitis in Pregnancy – case report and literature review. Skippen B and Tumuluri K. Accepted as poster for ESOPRS 2014 meeting, Budapest.
  • Necrotising dacryometaplasia of lacrimal gland – case report and literature review. Skippen B, Gal A and Tumuluri K. Accepted as poster for ESOPRS 2014 meeting Budapest.
  • Moorthy S, Allende A and Tumuluri K. Myxoid spindle cell tumour of orbit – rare case and literature review. Accepted as poster for ESOPRS 2014 meeting Budapest.
  • Whole Brain Radiotherapy Following Local Treatment of Melanoma Brain Metastases – Interim Analysis. K. DRUMMOND, G. B. Fogarty, A. Hong, K. Dolven-Jacobsen, C. H. Reisse, B. Burmeister, E. Paton, V. Steel, L. Haydu, H. Dhillon, B. Shivalingham, J. Vardy, A. Nowak, G. Hruby, R. Scolyer, C. Mandel, J. F. Thompson. ANZMTG 01.07 WBRTMel: Abstract Submission #7435393 accepted. 2014 Neurosurgical Society of Australasia's Annual Scientific Crown Perth Convention Centre, WA.

The Research Unit is currently co-ordinating several different research projects, including both pharmaceutical-sponsored clinical trials and in-house studies, as well as collaborative research projects. The Foundation provides a very unique platform for research, as the organisation not only accommodates for general dermatology services, but also specialised dermatology clinics and Mohs surgery. The Dermatopathology Department is also an extremely valuable asset for research at the Foundation, due to its large catalogue of common and unique cases of skin pathology, as well as the keen interest of staff members to undertake and assist with research projects.

Below is a description of the current research projects carried-out at the Foundation:

Scar Outcomes after Dermatological Surgery (SODS) (HREC 05-2009/11662)
Clinical research to improve scar outcomes is a high priority for the Foundation, since unfortunately scars are unavoidable when surgery is performed on the skin (and no patient likes having a scar). Therefore, it is important to carry-out research in this area to identify different ways to reduce the presence and visibility of scars, to inturn improve the clinical outcome for our patients.

The Scar Outcomes study is an in-house project evaluating the cosmetic outcomes of Dermatological Surgery. This study examines and compares different variables affecting the clinical outcome of a scar, including suture type, site on the body, size of the excision and closure type. Dr Daniel Hewitt and Dr Rob Paver are currently recruiting patients for this study, and we are hoping to have around 200 patients enrolled by the end of the year.

Closure technique, and tumor size and site
The closure technique, tumor size and site is spin-off of two studies, one already complete (Factors inviolve in Mohs surgery defect closure) and another near completion (Scar outcomes after Dermatological Surgery). This will establish benchmarks for other physicians that practice dermatological surgery.

The Cost-Effectiveness in Mohs Surgery
Mohs surgery is a highly specialised surgical technique suitable for the removal and treatment of non-melanoma skin cancers. The Skin & Cancer Foundation is one of the largest Mohs surgery facilities in Australia. The Foundation is also an approved Mohs College training centre, providing a “Mohs surgery Fellowship” for qualified dermatologists. The cost-effectiveness in Mohs surgery study compares the relative cost-efficacy of Mohs surgery compared to traditional excisions for skin cancers. Data is still being collected for this study, however, we expect that the cost for Mohs surgery will be similar if not lower than standard skin excisions, even though initially the cost of Mohs surgery is much greater. Analysis of the data should be complete by the end of 2012. 

Mechanisms in the Development of Grover’s Disease (Transient Acantholytic Dermatosis) in Patients on BRAF Inhibitors
This study is looking at the mechanisms of Grover’s disease development in patients on BRAF inhibitors.  This is a collaborative research project involving Westmead hospital, the research unit at the SCFA, along with Prof. Steven Kossard and our dermatopathology laboratory. Recently, the ethics application was approved and the data is now being collected for this study.


Recently Completed Research Projects and Clinical Trials

Intra-individual comparison of efficacy and safety of Metvix® natural daylight photodynamic therapy versus conventional Metvix® photodynamic therapy in subject with mild actinic keratoses (RD.03.SPR.29102)
This study, nick-named “The CoMet trial” compared the safety and efficacy of natural daylight photodynamic therapy with conventional photodynamic therapy (using Metvix), in patients with actinic keratosis. The Skin & Cancer Foundation Australia was one of 8 sites around Australia involved in this clinical trial. It is sponsored by Galderma and Dr Daniel Hewitt from our Westmead clinic was the principle investigator. The clinical trial data, which is currently being analysed for this study, will be published in 2013.

Efficacy of Lignocaine/Tetracaine cream, penthrox inhaler, and cold air blower for pain management during Facial Broadband Light Laser
This is an observational study looking at patients’ perception of pain before and after broadband light (BBL) laser therapy. The patients were asked to complete a short-form McGill Pain Questionnaire after receiving BBL treatment on their full-face. The data collection for this study is complete, and the results are currently being evaluated by the research department. 

Satisfaction study of laser therapy (HREC 05-2009/11662)
The use of lasers in the treatment of skin conditions is becoming very prevalent in dermatology. The following study was undertaken to evaluate effectiveness of laser treatments in selected cutaneous conditions. This study also investigated patient satisfaction after laser therapy as well as the quality of life of patients with certain skin conditions.

Data collection for this study is complete and the results of this research were presented at the Annual Meeting for the Australasian College of Dermatologists in 2011.

'A trusted reputation for excellence and expertise’

The Skin & Cancer Foundation Australia is a specialist dermatology centre with a number of highly qualified and internationally recognised experts in dermatology and the pharmacological aspects of skin diseases. Our experience makes us well placed to assist consumers in choosing skin care products that are safe to use and that deliver promised benefits.

Our organisation is well respected and association with our reputation, can assist clients to partner with the Foundation. and display our logo on their skin care products.

Review of product or service for partnership.

All products reviewed by our Research Unit with respect to its effectiveness and the accuracy of its product information and marketing statements to ensure that we are partnering with a reputable company with reputable products.

Once a product meets our criteria, the supplier is then entitled to place our logo prominently on their packaging. 

The supporter may also use the logo in advertising and promotional material.  The products are then associated with our reputation for medical excellence and independence and assist in funding our research and education activities. Some of these products can be purchased through an Online Shop. A portion of the sale of every product is given to the Foundation to help us achieve our mission to improve the skin health of Australians. To view the range of products available for purchase, click on the Online Shop tab at the top of the page.

The Foundation charges an annual fee for each product. The fee is negotiated for each individual product and is determined by considering the value of that partnership to the product supplier.  All fees are used by the Foundation to support its charitable objectives for our research and education activities. 

For further information about the Foundation's Product Partners Program, please contact the Foundation’s Business Development Manager at This email address is being protected from spambots. You need JavaScript enabled to view it.

Back to Top
Made by Forum Websites
Websites and Maintance Contracts